super. ace

LINCOLN — Nebraska receivers coach Garret McGuire has chosen to leave for a different job rather than take an adjusted role within the program, a source confirmed Thursday to the World-Herald. According to Football Scoop, McGuire, one of the youngest assistants in major college football, will be working for his dad, Texas Tech coach Joey McGuire. On Wednesday, NU coach Matt Rhule announced the hire of receivers coach Daikiel Shorts from Kentucky. Shorts will take the job previously held by McGuire, who coached Husker receivers for two seasons. Rhule said he hired Shorts because new Husker offensive coordinator Dana Holgorsen requested it. Holgorsen is set with the rest of the offensive staff, Rhule said, although they might pursue jobs of their own accord. McGuire was a backup quarterback under Rhule at Baylor 2017-2020 before working with Rhule for two seasons in Carolina. McGuire then followed Rhule to Nebraska where, at 24 years old, he became an assistant. NU touted his ability to relate to the players on the team while rebuffing the idea he couldn’t be stern. People are also reading... Nebraska transportation director: Expressway system won't be done until 2042 Blue Springs family to host 2025 Cattleman's Ball At the courthouse, Nov. 30, 2024 Shoplifting investigation leads to arrest for possession of controlled substance 27-year-old Beatrice man sentenced for May assault They fell in love with Beatrice. So they opened a store in downtown. Nebraska football signing day preview: Potential flips and a 5-star up for grabs Hospice foundation helps with extra support Gage County Sheriff's Office helps catch Fairbury suspect Mother to Mother supporting families 'The Message' religious sect sprouts destructive groups across globe Beatrice company seeks to break China's stranglehold on rare-earth minerals At the courthouse, Nov. 23, 2024 Shatel: Emotions are still simmering, but Nebraska delivered the bottom line for 2024 — a bowl game Black Friday starts a busy weekend of serving customers “He’s had a lot of people question him,” Rhule said in April ’23. “Which, honestly, hurts us in recruiting. We’re out there recruiting, and people are following us and they’re like ‘well, I keep hearing this narrative coming from our people, so we have to battle that a little bit.” This season, McGuire landed transfers Jahmal Banks and Isaiah Neyor out of the portal and out of high school Jacory Barney, who set the school’s freshman record for catches. Nevertheless, receivers’ blockers received criticism from fans and from Holgorsen himself upon arrival. “I’m like, ‘Why are you not blocking worth a crap on the perimeter?’” Holgorsen said Nov. 19. “It’s embarrassing.” Get local news delivered to your inbox!I'M A CELEB viewers were left horrified when they tuned in tonight to see Rev Richard and Tulisa forced to eat the body parts of mice and spiders. Both stars were selected for the dreaded food challenge, which sees contestants forced to eat unusual cuisine without throwing up. Viewers expect the Bushtucker Trials to be disgusting, but this year fans of the show found themselves unable to watch as Rev Richard choked back mice feet. Then things got even worse as Tulisa had to chow down on a selection of spiders. Fans flocked to social media to complain that production was "taking the p*ss", as they agreed that the game had gone too far. One disgusted audience member at home hit out: "Physically couldn’t watch Richard eat the mice tails/legs I started gagging. read more in I'm A Celeb "AND TULISA AND THE SPIDERS EW?!" Another chimed in: "F**king mice tails, production are taking the piss this year." A shocked viewer added: "This is by far the most disgusting eating trial ever Jesus Christ the tails nahhhh." A second agreed: "This has to be one of the worst eating trials in years." Most read in I’m A Celebrity 2024 Someone else screamed: "THE SPIDERS NO WHAT THE F**K THATS SICK THESE EATING TRIALS ARE ON ANOTHER LEVEL TF." Despite facing such a daunting task, Tulisa and Rev Richard both powered through and managed to win 11 stars for their team mates back at camp.When Taylor Swift and Travis Kelce's romance first began, some fans felt like it was a romantic-comedy plot come to life. Well, now, it might be just that. Lifetime's "Christmas in the Spotlight," which premiered on the network Nov. 23, is seemingly inspired by the popular couple. The film focuses on mega pop-star Bowyn Sykes (Jessica Lord), who has blond hair, bright red lips and often sports a cat-eye. Bowyn is at the height of her career, focused on making music her fans love, baking for fun and not looking for a new boyfriend after being tired of only dating “serious actors and indie rockers.” Meanwhile, Drew "Gonzo" Gonville (Laith Wallschleger) is one of the best wide receivers in the league who, from the outside, seems like a playboy, but he really loves hanging out with his family and niece. The end credits of the movie state, "The characters and events depicted in this motion picture are fictional. Any similarities to actual persons or animals living or dead are purely coincidental." The movie's writer Eirene Tran Donohue told USA Today that after seeing Swift cheering on Kelce during a football game, she thought, "This could be a rom-com." "I was like, ‘Christmas and Taylor Swift?' These are the two great loves of my life," she said. Speaking to the Associated Press , Tran Donohue said, "It’s clearly inspired by Taylor and Travis, but I don’t know them, and I don’t know what is going on behind the scenes." But she said she wrote the script for Swift fans. “There are so many Easter eggs,” she told AP. “I put in as many as I could.” Here's a roundup of all the apparent references to Swift, Kelce and their headline-making relationship. 'Arrows' Like Swift's Swifties, Bowyn's fans also have a nickname — "Arrows" or "Arrow heads." ("Bows, arrows, Bowyn's arrows, get it?" one character explains at the start of the film.) Arrowhead is also notably the name of the Kansas City Chiefs' stadium, and the place where Swift and Kelce went public with their relationship. Drew's jersey number The male lead of "Christmas in the Spotlight" plays for the fictional Bay Spring Bombers. His jersey number doesn't emulate Kelce's (No. 87) but rather, Swift's lucky number, 13. How the pop star and football player meet In "Christmas in the Spotlight," Bowyn and Drew meet backstage at one of her concerts. Drew then attempts to get Bowyn’s attention after their brief meet up backstage by inviting her to a game over social media. While, Swift and Kelce famously did not meet at the "Eras Tour," their relationship was set in motion after the tight end shared that he tried and failed to pass along his phone number while at her show . References to Swift lyrics During one of their first meetings, Bowyn tells Drew, “Growing up, I was never really the cheerleader type, more of a bleacher girl. Kind of a nerd to be honest," paralleling Swift's line "She's cheer captain and I'm on the bleachers," from her song "You Belong with Me." On their first date, which just so happens to be in Bowyn's private jet, the two have a myriad of song lyric interactions relating to Swift's "I Can Do It With a Broken Heart ." Bowyn says, "I'm a tough kid." Then, Drew notes, "You look like you’re having the time of your life." Newscasters in the film are also given seemingly Swift inspired names: Chad Marcus (" Chloe or Sam or Sophia or Marcus ") and Aimee Hannah (" Thank You Aimee "). Later in the film, the characters' dialogue references songs including, but not limited to: "The Alchemy," "You're Losing Me," "Wonderland," "All Too Well," "Mean" and more. Cheering him on Bowyn and Drew's blissful romance faces its first challenge when he wants to go public, but Bowyn isn't ready yet, maintaining that she values her privacy too much. The couple breaks up, but the world is still unaware they were ever together. While Bowyn privately mourns the relationship, the media begins speculating when she will release her next "catchy break up" song. Angry at the media and missing Drew, Bowyn decides to show up at his game and surprise him, sitting in his family box. (Swift and Kelce famously went public after she attended the Chiefs-Bears matchup at Arrowhead Stadium Sept. 24, 2023 . She's since become a fixture in the box at Chiefs home games.) In the film, Drew, who initially wasn't having a great game, immediately turns it around after seeing Bowyn. After he scores a touchdown, Drew strikes Kelce's signature archer pose, which Swift has also made on stage during her aptly-titled song, "The Archer." While in the family box, Drew's mom takes the time to tell Bowyn, "I know he’s got a bit of a reputation, but he’s got a good heart," dropping the name of Swift’s sixth album. An out of context phone call Now public with their relationship, Bowyn and Drew start supporting each other at their respective games and concerts. The media starts speculating if it’s a PR relationship and the public begins to get invested . When the duo attends a party for a brand celebrating their “best things issue,” Drew leaves the event early after a misunderstanding. Meanwhile, Bowyn is intercepted by her actor ex-boyfriend. Her ex begins questioning why she's with a football player and insulting Drew, but she quickly shuts him down. "He is a better man than you in every way and I’ve never been happier," she says (either accidentally or purposely referencing two Swift songs, "Better Man" and "Happiness"). Things start to look up after Bowyn and Drew make up, and the wide receiver is offered a contract with a football team in Los Angeles, potentially putting them in the same city. Then, Bowyn's ex leaks an edited recording of a conversation the two of them had in which she sarcastically says she is only with Drew for publicity reasons. He conveniently doesn't release the parts of the conversation where she defended Drew. While initially heartbroken, Drew finally believes Bowyn after his brother (also a football player) and sister-in-law show him the full video, proving she tried to defend him. This moment could be a reference to the phone call audio Kim Kardashian leaked in 2016 between Swift and Ye, formerly known as Kanye West, over the rapper using her name in his song "Famous." The footage caused the internet to turn on Swift, beginning the #TaylorSwiftIsOverParty trending hashtag. In 2020, the full, unedited clip was released online. Friendship bracelets After the truth is revealed, Drew resigns himself to thinking Bowyn is out of his league. Before Drew's football game and a Christmas gala he was supposed to host (notably featuring Bowyn as a guest performer), his niece gives him a friendship bracelet for good luck, spelling out an indecipherable mix of letters. Drew's brother is confused by what it means, but the niece clarifies: "It's an abbreviation of a Bowyn lyric. Don't you know anything?" Friendship bracelets have become a staple accessory — often with acronyms for notable songs and lyrics — for the "Eras Tour" after Swift's song " You're On Your Own, Kid " referenced making them. A song inspired by their romance In the grand finale of the film, Bowyn sings a Christmas love song at the gala and reveals she wrote it about Drew. (While Swift never confirms the inspiration for her songs, fans speculate that her songs "The Alchemy" and "So High School" are about Kelce.) The only snag for Bowyn? She's been told Drew isn't actually at the event and backed out of hosting. Nevertheless, she gives a speech declaring her love in the hopes he is watching a livestream of her performance. (During each "Eras Tour" show, fans can often find a livestream on social media of the show filmed by a concert attendee.) But surprisingly, Drew is there and catches her declaration of love. "I will always be your biggest cheerleader," he says, tying back to Swift's "You Belong With Me" once more, before asking her, "Are we doing this?" Bowyn responds, "Let's freaking go" — a PG version of a phrase Swift was caught on camera appearing to say after the Chiefs scored a touchdown in September 2023.super. ace 。

Blue Square X Expands Art Curation Services at Art Basel MiamiWhile rent price growth has slowed in the past year, the cost of renting remains significantly higher compared with pre-pandemic times. However, there are still suburbs close to the city with affordable rental properties. According to recent data from PropTrack, national weekly rents rose by 7 per cent in the past year, reaching $620 in November SIGN UP NOW FOR OUR FREE REAL ESTATE NEWSLETTER This was just half the growth rate of the prior year, marking a slowdown in market conditions. In Adelaide, annual rent growth from November 2023 to November 2024 was 9 per cent, down from 10 per cent the previous year. Yet, weekly rents remain 1.5 times higher than February 2020. Finding an affordable property has become more difficult, but homes in a number of inner-ring suburbs, those within the closest third in terms of distance to the CBD, still offer reasonably priced options. PropTrack economic analyst Megan Lieu. Supplied For suburbs within 8km of Adelaide CBD, Kilburn, Croydon Park, and Enfield offer the cheapest rental houses at $525, $550, and $580 per week, respectively. Enfield, Everard Park and Kurralta Park topped the list for the most affordable rental units among inner-ring suburbs. The cost of renting a unit was $395, $395 and $400 per week respectively. The increase of rental stock has been one key factor easing rental conditions. Since November 2023, total rental listings have risen by 7.1 per cent, likely due to a return of investors and more people opting to purchase their first home instead of renting. You can still get an affordable rental close to the city. Picture: Stephen Brookes However, on a historic basis, demand is high and supply remains low. As cost-of-living pressures mount and rents continue to outpace wage growth, more people will seek out cheaper rentals which could result in stronger price increases in budget-friendly areas. This will further decrease the availability of affordable rentals. To ensure that all Australians have access to affordable housing, the government must prioritise building more well-located homes to meet the demands of our growing population. – Megan Lieu is PropTrack’s economic analyst.None

None

For the first time since the season opener, the Winnipeg Jets' place atop the Central Division standings is in jeopardy. Winnipeg will aim to shed its recent struggles and maintain its lead in the Central when it visits the division rival Dallas Stars on Sunday. The Jets enter Saturday clinging to a two-point lead over second-place Minnesota, which hosts Nashville later that night. Winnipeg has gone just 3-5-0 since starting the season historically hot. During their record-breaking 15-1-0 start, the Jets averaged 4.56 goals per game while allowing just 2.13. However, that script has flipped, with Winnipeg now scoring only 2.5 goals per game and allowing 3.25. November's grueling schedule, which wrapped up in Las Vegas on Friday with a mistake-filled 4-3 loss to the Golden Knights, has taken a toll. Heading into Dallas, the Jets have played just one home game in their last nine, but the team knows they have to battle through it. "It's been such a grind. Just coming off the four (games) in six (days)," Jets head coach Scott Arniel said after the defeat in Las Vegas. "We're going into Dallas. We're going against a team in our division ... we have to make sure that we want to finish this road trip off on a good note." On this six-game road trip, the Jets are 2-3. "We know what Dallas is. Their building is not easy to play in," said Jets forward Cole Perfetti, who snapped an 11-game goal drought with two on Friday. "They're a tough team. It's a huge division game. The bare minimum we want to go home is .500. ... We have a chance to do it, so we have to make sure that we're ready come Sunday afternoon. I think we will be. I think we know how much that game is going to mean and carry the momentum coming home." While the Jets have struggled, Dallas has been bouncing back. After a deflating 6-2 loss to last-place Chicago on Wednesday, the Stars responded by holding off a third-period comeback attempt by Colorado to win 5-3 on Friday in Dallas. "It's a great group for responding to adversity," Stars coach Pete DeBoer said. "When we have a bad night, or a couple bad nights, you always know you're going to get their best ... I thought we had good detail in our game, did a good job bottling up the neutral zone ... we had a lot of contributions." Defenseman Miro Heiskanen tallied two assists in Friday's win and extended his point streak to four games. "We knew that we didn't play great in Chicago. We wanted to bounce back right away and not let too many games slip from us," Heiskanen said. "It's work ethic and trying to get back to what we're good at. It's been good for a couple years and hopefully we can keep doing that." Dallas forward Logan Stankoven will miss his second straight game due to a lower-body injury. Winnipeg might be without Nikolaj Ehlers, who is day-to-day with a lower-body injury after leaving Friday's game following an awkward fall into the boards. The Jets won the first meeting between these teams this season, a 4-1 result in Winnipeg on Nov. 9. --Field Level MediaCharbone Hydrogen secures warrant proceeds, extends expiry dates, and grants stock options announced $371,150 from warrant exercises expiring in late 2024 and early 2025. The company is extending the expiry dates of 9.98M warrants to February 28, 2025, and lowering their exercise price from $0.20 to $0.125, with TSX approval. Charbone also granted 1.75M stock options to team members, priced at $0.15, exercisable from December 2024. Updates to its private placement include insider participation of 1.26M units by CFO Benoit Veilleux and Director Mena Beshay, with finders’ warrants exercisable at $0.05 for 12 months. New Food and Drug Administration (FDA) guidance on accelerated approval for drugs targeting “serious conditions” appears to be a positive move for rare diseases, analysts at Jefferies believe. The FDA earlier this month published the draft guidance on its policies and procedures for the accelerated approval (AA) pathway for drugs for serious conditions that fulfil an unmet medical need. The analysts wrote that it is notable that both the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have jointly published the guidance. They wrote, The 2024 FDA guidance on AA builds on prior guidance from 2014 but places more emphasis on a few important changes, Jefferies highlighted. The agency encourages early communication with sponsors, ideally as early as post-Phase 1, regarding the eligibility of drugs for AA. This signals a more collaborative approach from the FDA, the analysts believe. For rare diseases, the FDA has introduced the Rare Disease Endpoint Advancement Pilot Program, allowing sponsors to propose surrogate or intermediate endpoints, which highlights the agency’s willingness to work closely with developers in these areas. Additionally, the FDA is now more open to considering a broader range of evidence, such as preclinical animal models and epidemiological data, when evaluating drugs for AA. However, the guidance also notes that AA is not suitable for every serious disease, especially if there is insufficient evidence to support a surrogate endpoint or if confirmatory trials are “infeasible.” Furthermore, the FDA has the authority to withdraw AA status if post-marketing requirements are not fulfilled, such as failing to complete confirmatory trials or if the drug turns out to be unsafe or ineffective. The analysts wrote, “In our view, all indication areas theoretically stand to benefit, though we think the rare disease space seems like a prime beneficiary, and not just gene therapies for rare diseases either.” They pointed to several notable rare disease programs, including Dyne Therapeutics and . Dyne is pursuing accelerated approval pathways for treatments targeting Myotonic dystrophy type 1 and Duchenne Muscular Dystrophy (DMD), while Sarepta has already received accelerated approval for its gene therapy Elevidys for DMD and is looking to extend this approach to other diseases like Limb-Girdle Muscular Dystrophy. Analysts wrote, the latest news shaping the hydrogen market at Charbone Hydrogen secures warrant proceeds, extends expiry dates, and grants stock options, AI platform accelerating approval procedures for hydrogen projects Hydrogen centre Hamburg developing a digital infrastructure for planning and approval The Ministry of Urban Development and Housing is working on an AI... Germany Scraps €350 Million in Subsidies for Hydrogen Projects (Bloomberg) — Germany abandoned plans to funnel €350 million ($368 million) into hydrogen projects, putting clean-fuel goals even further from reach. The... EUROPE – TECO 2030, hydrogen fuel-cell manufacturer, files for bankruptcy amid funding challenges Norwegian maritime clean tech company TECO 2030 ASA has announced that its board of directors has unanimously...By MICHAEL R. SISAK and JENNIFER PELTZ NEW YORK (AP) — President-elect Donald Trump’s lawyers urged a judge again Friday to throw out his hush money conviction, balking at the prosecution’s suggestion of preserving the verdict by treating the case the way some courts do when a defendant dies. They called the idea “absurd.” Related Articles National Politics | Trump wants to turn the clock on daylight saving time National Politics | Ruling by a conservative Supreme Court could help blue states resist Trump policies National Politics | A nonprofit leader, a social worker: Here are the stories of the people on Biden’s clemency list National Politics | Nancy Pelosi hospitalized after she ‘sustained an injury’ on official trip to Luxembourg National Politics | Veteran Daniel Penny, acquitted in NYC subway chokehold, will join Trump’s suite at football game The Manhattan district attorney’s office is asking Judge Juan M. Merchan to “pretend as if one of the assassination attempts against President Trump had been successful,” Trump’s lawyers wrote in a blistering 23-page response. In court papers made public Tuesday, District Attorney Alvin Bragg’s office proposed an array of options for keeping the historic conviction on the books after Trump’s lawyers filed paperwork earlier this month asking for the case to be dismissed. They include freezing the case until Trump leaves office in 2029, agreeing that any future sentence won’t include jail time, or closing the case by noting he was convicted but that he wasn’t sentenced and his appeal wasn’t resolved because of presidential immunity. Trump lawyers Todd Blanche and Emil Bove reiterated Friday their position that the only acceptable option is overturning his conviction and dismissing his indictment, writing that anything less will interfere with the transition process and his ability to lead the country. The Manhattan district attorney’s office declined comment. It’s unclear how soon Merchan will decide. He could grant Trump’s request for dismissal, go with one of the prosecution’s suggestions, wait until a federal appeals court rules on Trump’s parallel effort to get the case moved out of state court, or choose some other option. In their response Friday, Blanche and Bove ripped each of the prosecution’s suggestions. Halting the case until Trump leaves office would force the incoming president to govern while facing the “ongoing threat” that he’ll be sentenced to imprisonment, fines or other punishment as soon as his term ends, Blanche and Bove wrote. Trump, a Republican, takes office Jan. 20. “To be clear, President Trump will never deviate from the public interest in response to these thuggish tactics,” the defense lawyers wrote. “However, the threat itself is unconstitutional.” The prosecution’s suggestion that Merchan could mitigate those concerns by promising not to sentence Trump to jail time on presidential immunity grounds is also a non-starter, Blanche and Bove wrote. The immunity statute requires dropping the case, not merely limiting sentencing options, they argued. Blanche and Bove, both of whom Trump has tabbed for high-ranking Justice Department positions, expressed outrage at the prosecution’s novel suggestion that Merchan borrow from Alabama and other states and treat the case as if Trump had died. Blanche and Bove accused prosecutors of ignoring New York precedent and attempting to “fabricate” a solution “based on an extremely troubling and irresponsible analogy between President Trump” who survived assassination attempts in Pennsylvania in July and Florida in September “and a hypothetical dead defendant.” Such an option normally comes into play when a defendant dies after being convicted but before appeals are exhausted. It is unclear whether it is viable under New York law, but prosecutors suggested that Merchan could innovate in what’s already a unique case. “This remedy would prevent defendant from being burdened during his presidency by an ongoing criminal proceeding,” prosecutors wrote in their filing this week. But at the same time, it wouldn’t “precipitously discard” the “meaningful fact that defendant was indicted and found guilty by a jury of his peers.” Prosecutors acknowledged that “presidential immunity requires accommodation” during Trump’s impending return to the White House but argued that his election to a second term should not upend the jury’s verdict, which came when he was out of office. Longstanding Justice Department policy says sitting presidents cannot face criminal prosecution . Other world leaders don’t enjoy the same protection. For example, Israeli Prime Minister Benjamin Netanyahu is on trial on corruption charges even as he leads that nation’s wars in Lebanon and Gaza . Trump has been fighting for months to reverse his May 30 conviction on 34 counts of falsifying business records . Prosecutors said he fudged the documents to conceal a $130,000 payment to porn actor Stormy Daniels to suppress her claim that they had sex a decade earlier, which Trump denies. In their filing Friday, Trump’s lawyers citing a social media post in which Sen. John Fetterman used profane language to criticize Trump’s hush money prosecution. The Pennsylvania Democrat suggested that Trump deserved a pardon, comparing his case to that of President Joe Biden’s pardoned son Hunter Biden, who had been convicted of tax and gun charges . “Weaponizing the judiciary for blatant, partisan gain diminishes the collective faith in our institutions and sows further division,” Fetterman wrote Wednesday on Truth Social. Trump’s hush money conviction was in state court, meaning a presidential pardon — issued by Biden or himself when he takes office — would not apply to the case. Presidential pardons only apply to federal crimes. Since the election, special counsel Jack Smith has ended his two federal cases , which pertained to Trump’s efforts to overturn his 2020 election loss and allegations that he hoarded classified documents at his Mar-a-Lago estate. A separate state election interference case in Fulton County, Georgia, is largely on hold. Trump denies wrongdoing in all. Trump had been scheduled for sentencing in the hush money case in late November. But following Trump’s Nov. 5 election victory, Merchan halted proceedings and indefinitely postponed the former and future president’s sentencing so the defense and prosecution could weigh in on the future of the case. Merchan also delayed a decision on Trump’s prior bid to dismiss the case on immunity grounds. A dismissal would erase Trump’s conviction, sparing him the cloud of a criminal record and possible prison sentence. Trump is the first former president to be convicted of a crime and the first convicted criminal to be elected to the office.

Trump transition team says several Cabinet picks targeted with bomb threats and swattingRobbins LLP Informs Paycor HCM, Inc. Stockholders that it is Investigating the Officers and Directors of PYCR to Determine if They Breached Fiduciary Duties Owed to Shareholders

Police deny sitting on evidence as Netflix doc brings renewed attention to JonBenet Ramsey's killing

Bruce Willis spent his Thanksgiving with those who love him most. On Thanksgiving, his daughters Tallulah and Scout shared photos on social media with their father, where he is seen holding a desk plate that reads "Best Dad Ever." "Grateful," Tallulah Willis wrote in the caption on the photos. It was announced in 2022 that the actor would be stepping away from his career due to cognitive issues. He has since been diagnosed with frontotemporal dementia (FTD), which is a progressive brain condition. Rumer, Scout and Tallulah Willis are the 69-year-old star's adult daughters with his former wife, actress Demi Moore. Moore and Willis divorced in 2000. Willis has been married for more than 16 years to Emma Heming Willis, with whom he shares two young daughters, Mabel and Evelyn. Willis and Moore have remained close and their blended family often shares memories of family getherings on social media. The CNN Wire TM & © 2024 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.Mexico president hails 'excellent' Trump talks after US tariff threatPalvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately $80.0 million of cash and cash equivalents, including proceeds from a PIPE financing co-led by BVF Partners, L.P. and Frazier Life Sciences Cash expected to fund operations into the second half of 2027, including through Phase 3 SELVA clinical trial of QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) and Phase 2 clinical trial in cutaneous venous malformations (cutaneous VMs) Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. QTORINTM rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous VMs WAYNE, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol "PVLA". Palvella will continue to be led by Wes Kaupinen, its Founder and Chief Executive Officer, and other members of the Palvella management team. The transaction was approved by Pieris stockholders at a special meeting held on December 11, 2024, and the transaction had been previously approved by Palvella stockholders. "With strong support from leading healthcare-dedicated investors, Palvella is well positioned to enter the public markets and pursue our vision of becoming the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases," said Mr. Kaupinen. “This transaction will enable us to accelerate late-stage development of QTORINTM rapamycin, our lead product candidate, for microcystic LMs and cutaneous VMs while also further advancing additional novel product candidates from our QTORINTM platform." Concurrent with the merger, Palvella completed a previously announced oversubscribed $78.9 million private placement co-led by BVF Partners, L.P., an existing investor, and Frazier Life Sciences, a new investor, and with participation from a syndicate of leading healthcare-dedicated investors. Additional new investors include Blue Owl Healthcare Opportunities, Nantahala Capital, DAFNA Capital Management, ADAR1 Capital Management, and a healthcare dedicated fund. Existing investors Samsara BioCapital, Petrichor, CAM Capital, Ligand Pharmaceuticals, Integrated Finance Group (an AscellaHealth partner company), BioAdvance, and Gore Range Capital also participated in the financing. Palvella's cash and cash equivalents of approximately $80.0 million is expected to fund operations into the second half of 2027, including through results from the SELVA Phase 3 clinical trial of QTORINTM rapamycin for the treatment of microcystic LMs and Phase 2 clinical trial of QTORINTM rapamycin in cutaneous VMs. Palvella’s research team developed QTORINTM, a patented and versatile platform designed to generate novel topical therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of serious, rare genetic skin diseases. Well-accepted mechanisms of action of rapamycin and other therapeutic agents represent potential therapies for rare genetic skin diseases. However, the adverse event profile of those agents through systemic exposure poses significant barriers to patient adoption. Palvella’s QTORINTM product candidates are designed for targeted, localized delivery of therapeutic agents to pathogenic tissue of interest while minimizing systemic absorption and thereby reducing the risk of unwanted adverse events associated with systemic therapy. Palvella's lead product candidate QTORINTM rapamycin is a novel, patented 3.9% rapamycin anhydrous gel currently under development for the treatment of microcystic LMs, cutaneous VMs, and other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway. QTORINTM rapamycin has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for microcystic LMs and is the recent recipient of up to a $2.6 million FDA Orphan Products Grant. QTORINTM rapamycin has also received Fast Track Designation for venous malformations. QTORINTM rapamycin is protected by issued composition patents covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S., Japan, Australia, China and Israel and pending patent applications broadly covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S. and other countries. In the third quarter of 2024, Palvella initiated SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORINTM rapamycin administered once daily for the treatment of microcystic LMs. The primary efficacy endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment (mLM-IGA) at week 24. The Phase 3 study is enrolling approximately 40 subjects, age six or older, at leading vascular anomaly centers across the U.S. Transaction Details Based on the final exchange ratio of approximately 0.30946 shares of Pieris common stock for each share of Palvella common stock, at the closing of the merger, there are approximately 13.95 million shares of the combined company's common stock outstanding on a diluted basis, with prior Pieris stockholders owning approximately 11% on a diluted basis and prior Palvella stockholders (including investors in the private placement) holding approximately 89% of the combined company's outstanding common stock on a diluted basis. In connection with the closing of the merger, Pieris issued a non-transferable contingent value right (CVR) to Pieris shareholders of record immediately prior to the closing, which does not include the former holders of shares of Palvella or the private financing investors. Holders of the CVR will be entitled to receive payments from proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals, in addition to other potential licensing agreements involving certain of Pieris' legacy assets, as well as certain potential payments related to historical research and development tax credits, which may or may not be realized. TD Cowen served as lead placement agent and Cantor served as a placement agent for Palvella's concurrent financing. Troutman Pepper Hamilton Sanders LLP served as legal counsel to Palvella. Cooley LLP served as legal counsel to the placement agents. Stifel served as the exclusive financial advisor to Pieris and Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. served as legal counsel to Pieris. About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway. The disease is characterized by malformed lymphatic vessels that protrude through the skin and persistently leak lymph fluid (lymphorrhea) and bleed, often leading to recurrent serious infections and cellulitis that can cause hospitalization. The natural history of microcystic LMs are persistent and progressive without spontaneous resolution, with symptoms generally worsening during life, including increases in the number and size of malformed vessels that lead to complications and lifetime morbidity. There are currently no FDA-approved treatments for the estimated more than 30,000 diagnosed patients with microcystic LMs in the United States. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORINTM platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin), is currently in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase 2 trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow the Company on LinkedIn. QTORINTM rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella and Pieris, as well as assumptions made by, and information currently available to, management of Palvella and Pieris. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, the sufficiency of the combined company’s capital resources; the combined company’s cash runway; the expected timing of the closing of the proposed transactions; statements regarding the potential of, and expectations regarding, Palvella’s programs, including QTORINTM rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity; the expected timing of initiating, as well as the design of Palvella’s Phase 2 clinical trial of QTORINTM rapamycin in cutaneous venous malformations. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the limited operating history of each company; the significant net losses incurred since inception; the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORINTM rapamycin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of the global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella and Pieris to protect their respective intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Pieris’ most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, as well as the registration statement on Form S-4 filed with the SEC by Pieris in connection with the merger. Palvella and Pieris can give no assurance that the conditions to the proposed transactions will be satisfied. Except as required by applicable law, Palvella and Pieris undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. Palvella Therapeutics Contact Information Investors Wesley H. Kaupinen Founder and CEO, Palvella Therapeutics wes.kaupinen@palvellatx.com Media Stephanie Jacobson Managing Director, Argot Partners palvella@argotpartners.com

NoneAds jar epic documentary